Principal
The aim of our study was to evaluate the incidence of ≥ 4 pathological axillary lymph nodes in ER-positive, HER2-negative early BC patients treated by upfront surgery with SLNB and cALND grade 1-2, with involved SN by micro metastases or macro metastases ineligible for abemaciclib, according to clinicopathological criteria. Predictive factors of ≥ 4 pathological axillary lymph nodes were determined.
Secondaires
A predictive score of ≥ 4 involved LN macro metastases was created.
Institut Paoli Calmettes
232 Boulevard Sainte Marguerite
13273 Marseille Cedex 09
D’inclusion :
French cohort: Patients were retrospectively identified from a cohort of 17,097 ER-positive, Her2-negative early BC patients, who underwent upfront surgery in 13 French centers between 1990 and 2023. Patients with SLNB and cALND were selected. We then excluded patients eligible for abemaciclib according to the MonarchE trial criteria of pT3 and/or grade 3 with 1-3 pathological axillary lymph nodes. All patients in 13 French centers between 2001-2023, who underwent upfront surgery with SLNB and cALND, grade 1-2, with involved SN by micro metastases or macro metastases were included.
De non inclusion :
Critère d’évaluation principal :
Predictive factors of ≥ 4 pathological axillary lymph nodes
Critères d’évaluation secondaires :
the incidence of ≥ 4 pathological axillary lymph nodes in ER-positive, HER2-negative early BC patients treated by upfront surgery with SLNB and cALND grade 1-2, with involved SN by micro metastases or macro metastases ineligible for abemaciclib, according to clinicopathological criteria.
Traitement de données mené dans l'intérêt public dans le domaine de la santé publique (article 6.1e et 9.2.j du Règlement (UE) n°2016/679)
institut paoli calmettes
Les données seront conservées pendant la durée légale en vigueur ou tant qu'elles présenteront un intérêt scientifique